Goldman Small Cap Research Issues New Research Update on OKYO

Goldman Small Cap Research has issued an updated research report on OKYO Pharma Limited (NASDAQ:OKYO), raising its price target from $5.00 to $8.00. OKYO, a clinical-stage biopharma company focused on treatments for neuropathic corneal pain (NCP) and dry eye disease (DED), has seen its stock price double since January 2025. The company's lead drug candidate urcosimod received Fast Track designation and completed two Phase 2 trials - a 240-patient trial for DED and a 17-patient trial for NCP, with the latter concluding earlier than expected. Top-line results are now anticipated in Q3 2025, ahead of schedule. The early trial completion and accelerated data release timeline are viewed positively by analysts, who note the company's potential in the multi-billion-dollar ocular market and possibility for M&A activity in the space.

https://www.stocktitan.net/news/OKYO/goldman-small-cap-research-issues-new-research-update-on-okyo-pharma-0oksm49d46f9.html